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Introduction
Both HIV/AIDS and tuberculosis (TB) are leading causes 
of morbidity and mortality globally (1,2). In 2017, there 
were 8,965,800 new cases, 1,929,208,600 prevalent cases, 
and 1,183,700 deaths of TB, as well as 1,942,100 new cases, 
36,822,200 prevalent cases, and 954,500 deaths of HIV/
AIDS. Among all HIV/AIDS deaths, nearly 23% are related 
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to TB (1,2). HIV/AIDS, TB, and their co-infection are 
major global health concerns and have drawn the focus of 
the United Nations which made Sustainable Development 
Goal 3.3 to end HIV/AIDS epidemics by 2030. Continued 
surveillance is crucial in monitoring disease control efforts 
for both HIV/AIDS and TB. However, there has been 
insufficient attention placed on HIV/AIDS and TB co-
infection in previous disease-specific research such as the 
Global Burden of Disease (GBD) Study (3-5). 
When implementing control efforts for HIV/AIDS and 
TB, the East Asia and Pacific World Bank region plays an 
important role due to its high disease burden, particularly of 
TB (1-5). China and Indonesia, for example, are among the 
top ten countries in the world with the most prevalent cases 
of HIV/AIDS and are both top three countries worldwide 
with the most prevalent cases of TB in 2017 (6). As a region 
with high disease burdens of both HIV/AIDS and TB, the 
East Asia and Pacific region is also a high-risk region for 
their co-infection. In this article, we examined morbidity 
and mortality of HIV and TB co-infection in the East Asia 
and Pacific region from 1990 to 2017.
Methods
This study is based on the data and measures of the GBD 
Study 2017. In brief, the GBD Study series provide 
comprehensive global disease information by quantifying 
geographically-specific disease measures such as incidence, 
prevalence, and mortality, as well as disease burden 
attributable to risk factors by age, sex, and geography 
over time. The current study includes data collected from 
195 countries and territories from 1990 to 2017. Detailed 
information about the conception, design, data collection, 
and data synthesis of the GBD Study 2017 has been 
published elsewhere (1,2,7-11), and related information for 
HIV/AIDS, TB, and their co-infection has been described 
previously as well (3-5).
In this study, HIV and TB co-infection includes: HIV-
infected drug-susceptible tuberculosis (HIV-infected 
DS-TB), HIV-infected multidrug-resistant tuberculosis 
without extensive drug resistance (HIV-infected MDR-TB 
without XDR), and HIV-infected extensively drug-resistant 
tuberculosis (HIV-infected XDR-TB). We examined both-
sex incidence, prevalence, and deaths of HIV and TB co-
infection based on all-age number and age-standardized 
rate by three co-infection types from the GBD Study 2017 
data. We analyzed the trend of the three above measures 
for the period between 1990 and 2017 by using a join-
point regression model (version 4.6.0.0); a significant trend 
is indicated when the P value is lower than 0.05 (12,13). 
For HIV-infected DS-TB, the co-infection type with 
the highest burden, we conducted trend analysis for each 
measure (prevalence, incidence, and mortality) in the three 
countries with the highest number and the highest rate of 
that measure in 2017 (e.g., trend analysis for HIV-infected 
DS-TB incidence rate was conducted in Indonesia, Laos, 
and Myanmar, because their incidence rates of HIV-infected 
DS-TB were highest among all countries in the East Asia 
and Pacific region in 2017).
Results
Incidence, prevalence, and mortality of HIV and 
tuberculosis co-infection in 2017
Both-sex, all-age new cases, prevalent cases, and deaths of 
HIV-infected DS-TB, HIV-infected MDR-TB without 
XDR, and HIV-infected XDR-TB by countries in East 
Asia and the Pacific in 2017 are summarized in Table 1. In 
2017, there were 238,372, 4,294, and 392 new cases of HIV-
infected DS-TB, HIV-infected MDR-TB without XDR, 
and HIV-infected XDR-TB, respectively. The number of 
prevalent cases and deaths were 383,809 and 12,197 of HIV-
infected DS-TB, 7,811 and 1,168 of HIV-infected MDR-TB 
without XDR, and 713 and 282 of HIV-infected XDR-TB.
For HIV-infected DS-TB in 2017, the countries with 
the highest number of new cases were Indonesia (168,147 
cases), China (26,388 cases), and Myanmar (13,178 cases). 
The countries with the highest number of prevalent cases 
were Indonesia (246,729 cases), China (68,607 cases), and 
Vietnam (20,275 cases); and those with the highest number 
of deaths were Indonesia (2,994 deaths), Vietnam (2,485 
deaths), and China (2,212 deaths).
Both-sex, age-standardized incidence rate, prevalence 
rate and mortality rate (per 100,000 population) of the 
three HIV and TB co-infection types by countries in 
East Asia and the Pacific are summarized in Table 2. The 
age distribution of these three rates are shown for both-
sex, male-only, and female-only in Figure 1. For HIV-
infected DS-TB in 2017, the top three countries with the 
highest incidence rate were Indonesia (61.27 new cases per 
100,000), Laos (25.55 new cases per 100,000), and Myanmar 
(23.95 new cases per 100,000); those with the highest 
prevalence rate were also Indonesia (89.76 prevalent cases 
per 100,000), Laos (39.00 prevalent cases per 100,000), and 
Myanmar (33.88 prevalent cases per 100,000); and those 
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with the highest mortality rate were Myanmar (3.08 deaths 
per 100,000), Vietnam (2.23 deaths per 100,000), and 
Thailand (1.97 deaths per 100,000).
Incidence, prevalence, and mortality trends of HIV and 
tuberculosis co-infection from 1990 to 2017
The incidence, prevalence, and mortality trends of 
HIV and tuberculosis co-infection are shown based on 
number (Figures S1-S3) and rate (per 100,000 population; 
Figures 2-4) for the period between 1990 and 2017. These 
figures show both of global trends and trends in the East 
Asia and Pacific region. The results from trend analysis 
are summarized in Table S1. Overall, the incidence rates of 
HIV-infected DS-TB and HIV-infected MDR-TB without 
XDR (Figure 2), the prevalence rate of HIV-infected MDR-
TB without XDR (Figure 3), and the mortality rate of all 
three co-infection types (Figure 4) in East Asia and the 
Pacific were lower than the global rates for the past decade.
For HIV-infected DS-TB, the overall number and rate 
for incidence and prevalence have increased from 1990 
to 2017 (Table S1). More specifically, the prevalence rate 
of HIV-infected DS-TB was higher than the global level 
in recent years (2015–2017) (Figure 3). As for mortality, a 
Figure 2 The trend (1990–2017) of both-sex, age-standardized incidence rate (per 100,000 population) of HIV and tuberculosis co-infection in 
East Asia and the Pacific.
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significant increase began in 1990 (number: 2,156 deaths; 
rate: 0.12 deaths per 100,000) and reached its peak in 2005 
(number: 17,284 deaths; rate: 0.73 deaths per 100,000); since 
2005, mortality has significantly decreased (number in 2017: 
12,197 deaths; rate in 2017: 0.47 deaths per 100,000) (Table 
S1). The countries with the highest value of each disease 
measure (number and rate) in 2017 are shown in Table S2; 
most demonstrated a decreasing trend in the three most 
recent years. 
Each measure for HIV-infected MDR-TB without XDR 
showed a significant increase followed by a significant 
decrease after reaching a peak (Table S1). For example, 
the mortality rate of HIV-infected MDR-TB significantly 
increased from 0.0067 deaths per 100,000 in 1990, reached 
its peak (0.09 deaths per 100,000) in 2003, and then 
significantly decreased to 0.04 deaths per 100,000 in 2017.
The number of HIV-infected XDR-TB incident and 
prevalent cases as well as prevalence rate presented a 
continuous increase throughout the period (1990–2017); 
the incidence rate increased significantly from 1990 
to 2005 and then became steady (2005–2017). The 
mortality rate showed a continuous significant increase 
and then a significant decrease after reaching a peak in 
2012 (Table S1).
Figure 3 The trend (1990–2017) of both-sex, age-standardized prevalence rate (per 100,000 population) of HIV and tuberculosis co-infection in 
East Asia and the Pacific.
20
15
10
5
0
P
re
va
le
nt
 c
as
es
 p
er
 1
00
,0
00
0.050
0.040
0.030
0.020
0.010
0.000
P
re
va
le
nt
 c
as
es
 p
er
 1
00
,0
00
0.8
0.6
0.4
0.2
0.0
P
re
va
le
nt
 c
as
es
 p
er
 1
00
,0
00
1990 1992 1994 1996 1998 2000 2002 2004 2006 2008 2010 2012 2014 2016
Year
1990 1992 1994 1996 1998 2000 2002 2004 2006 2008 2010 2012 2014 2016
Year
1990 1992 1994 1996 1998 2000 2002 2004 2006 2008 2010 2012 2014 2016
Year
HIV/ AIDS - Drug-susceptible tuberculosis
Both sexes, age-standardized
HIV/AIDS - Multidrug-resistant tuberculosis without 
extensive drug resistance 
Both sexes, age-standardized
HIV/AIDS-Extensively drug-resistant tuberculosis
Both sexes, age-standardized
Global
East Asia & Pacific - WB
3831Journal of Thoracic Disease, Vol 11, No 9 September 2019
© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2019;11(9):3822-3835 | http://dx.doi.org/10.21037/jtd.2019.09.23
Discussion
Complete, timely, reliable, and valid surveillance is important 
to quantify the morbidity and mortality of HIV/AIDS 
and TB co-infection for disease control (14-17). This 
study provides up-to-date measure information including 
tendency of the co-infection in East Asia and Pacific by 
utilizing data and measures compiled by the GBD Study 
2017. We found that both-sex, age-standardized mortality 
rates of the three HIV/AIDS and TB co-infection types in 
East Asia and the Pacific were lower than global rates over 
the past decade. In addition, the trend in mortality (number 
and rate) in all co-infection types significantly decreased 
over the five most recent years of data. However, both the 
number and rate for incidence and prevalence of HIV-
infected DS-TB and HIV-infected XDR-TB have been 
increasing throughout the period (1990–2017).
The decreasing tendency of mortality demonstrates 
a remarkable progress in disease treatment. Since 
the introduction of antiretroviral therapy (ART), a 
lower mortality rate has been successfully achieved in 
HIV patients with and without TB (18-25). However, 
considering the co-infection of both diseases, especially 
Figure 4 The trend (1990–2017) of both-sex, age-standardized mortality rate (per 100,000 population) of HIV and tuberculosis co-infection in 
East Asia and the Pacific.
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HIV-infected MDR-TB (including HIV-infected XDR-
TB), treatment management is more complicated compared 
to the management of either disease on its own. The 
complication includes drug interactions, overlapping 
toxicity, and the possibility of immune reconstitution 
inflammatory syndrome (IRIS), which may potentially lead to 
drug resistance, nonadherence to therapy, and/or virological 
failure (26). To some extent, this complication explains why 
both the incidence rate and prevalence rate of HIV-infected 
XDR-TB have not declined over the last decade.
The increasing numbers and rates of incidence and 
prevalence of HIV-infected DS-TB and HIV-infected 
XDR-TB reflect the difficulty of prevention efforts. For 
example, the breakthrough discovery of highly active ART 
is able to reduce the size of the immunocompromised 
population and decrease the life-time risk of developing 
active TB (14). As a result, the World Health Organization 
(WHO) recommends an earlier initiation of ART to prevent 
active tuberculosis in people with HIV (27). However, the 
availability and distribution of these therapies vary—not all 
HIV patients receive the therapy, regardless of TB status 
(14,28). According to the GBD Study 2015, the global 
ART coverage per 100 people living with HIV in 2015 was 
40.6%, and the coverage in the high sociodemographic 
index (SDI) countries was 51.5%. However, the coverage in 
Southeast Asia, East Asia, and Oceania (major parts of the 
East Asia and Pacific region) was only 25.9%, lower than 
not only global coverage but also lower than coverage in 
low SDI countries (37.9%) (4).
To eliminate both HIV/AIDS and TB, as well as their 
co-infection, further efforts for treatment are needed. Main 
strategies should be: early use of ART, early testing to detect 
drug resistance, sustained adherence to appropriate drug-
resistant TB regimens, and proper monitoring for treatment 
response and adverse effects (17). Early use of ART has been 
difficult to implement due to low ART coverage, reflecting 
the limited available resources globally (28,29) and in East 
Asia and the Pacific, especially in regions with the highest 
disease morbidity and mortality such as Myanmar (30) 
and some regions of China (e.g., Xinjiang Province) (31). 
As for early detection of drug resistance, although a rapid 
detection of TB and drug resistance in patients living with 
HIV has been well established (e.g., Xpert MTB/RIF) (32), 
one major barrier for a broader implementation is the cost 
(33,34). To achieve sustained adherence to TB regimens 
and proper monitoring for treatment response and adverse 
effects, programmatic management is recommended. The 
Cambodian National MDR-TB program is one example of 
a successful program that achieved treatment success based 
on a community-based effort (35).
To achieve the above treatment strategies, main barriers 
to disease control should be targeted. In addition to limited 
resources (e.g., ART coverage, cost, well-established 
programmatic management), efforts should also focus 
on stigma. Stigma is a substantial challenge for HIV 
diagnosis and treatment (36-39). This increases the risk 
of developing TB, and the risk of new HIV/AIDS (and, 
consequentially, TB) cases through infection. Reducing 
stigma requires respectful and targeted engagement, 
especially for marginalized populations [sex workers, men 
who have sex with men (MSM), transgender people, people 
who inject drugs, and people in prison] (40). For this, legal 
and social environments play an important role, especially 
those involving health professionals (40,41). Incarceration 
is another major obstacle. According to a systematic review 
and meta-analysis, the prevalence of HIV/AIDS and TB co-
infection among incarcerated individuals is high worldwide: 
32.6% globally, and 35% in Asia (42). One reason 
accounting for such a high prevalence is that incarceration 
is a main risk factor of developing TB, especially among 
those who contracted HIV/AIDS via drug injection (43,44). 
Other reasons include limited resources for diagnosis and 
treatment adherence, low treatment completion rate due 
to limited resources as well as movement by individuals 
into and out of the prison system (42,45). In addition to the 
above barriers, an evidence gap between research outputs 
and policy also exists. A study in Cambodia found that only 
a small proportion of TB research outputs addressed policy 
and program planning (46). This study indicates substantial 
room for improvement in alignment between researchers, 
funders, and policy makers.
This study has several limitations. First, we followed the 
GBD study methods using aggregated data from the GBD 
website. Detailed limitations on the GBD study’s methods 
have been well discussed in pervious publications (1-11). 
Second, the distribution of HIV/AIDS and TB co-infection 
is heterogeneous between local regions within each country 
and the present results using GBD Study measures only 
demonstrate a country-level picture of the co-infection 
in East Asia and the Pacific. Furthermore, we did not 
provide estimates of the co-infection by age and sex for 
each country. However, detailed estimates are available on 
the GBD website (http://ghdx.healthdata.org/gbd-results-
tool). For further improvement of our future research, 
it is reasonable to consider those measures among more 
vulnerable populations, including incarcerated populations.
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Conclusions
HIV/AIDS, tuberculosis, and their co-infection constitute 
a substantial portion of global morbidity and mortality. 
Our study indicates that the trends in almost all measures 
of the three co-infection types examined here have been 
decreasing globally, and their trends in mortality have also 
been decreasing in East Asia and the Pacific. However, 
the overall trends in both incidence and prevalence of 
HIV-infected DS-TB and HIV-infected XDR-TB have 
been increasing since 1990. Continuous efforts should be 
kept in progress for disease control. For example, further 
development of treatments specifically for co-infection and 
management protocols, as well as cost containment, are 
needed to reverse the current increasing trends of these co-
infection types.
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Figure S1 The trend (1990–2017) of both-sex, all-age new cases of HIV and tuberculosis co-infection in East Asia and the Pacific.
Figure S2 The trend (1990–2017) of both-sex, all-age prevalent cases of HIV and tuberculosis co-infection in East Asia and the Pacific.
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Figure S3 The trend (1990–2017) of both-sex, all-age deaths of HIV and tuberculosis co-infection in East Asia and the Pacific.
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Table S1 Trend analysis on the number and rate of incidence, prevalence and mortality (1990–2017) of HIV and tuberculosis co-infection in East Asia and the Pacific 
Measures
Trend 1 Trend 2 Trend 3 Trend 4 Trend 5 Trend 6
Years Slope Years Slope Years Slope Years Slope Years Slope Years Slope
HIV-infected drug-susceptible tuberculosis (HIV-infected DS-TB)
New cases 1990–1994 21,970** 1994–1998 11,595** 1998–2005 8,404** 2005–2009 758* 2009–2017 2,034** – –
Incidence rate 1990–1993 1.068** 1993–1996 0.593** 1996–2002 0.342** 2002–2005 0.276** 2005–2010 −0.012 2010–2017 0.074**
Prevalent cases 1990–1994 26,234** 1994–1999 17,888** 1999–2004 13,177** 2004–2009 9,472** 2009–2013 6,658** 2013–2017 4315**
Prevalence rate 1990–1993 1.248** 1993–1996 0.826** 1996–1999 0.660** 1999–2004 0.501** 2004–2009 0.315** 2009–2017 0.184**
Deaths 1990–1996 1,382** 1996–1999 1,120** 1999–2002 818** 2002–2005 408* 2005–2012 −462** 2012–2017 −368**
Mortality rate 1990–1995 0.068** 1995–1999 0.045** 1999–2002 0.026** 2002–2005 0.009 2005–2010 0.026** 2010–2017 −0.019**
HIV-infected multidrug-resistant tuberculosis without extensive drug resistance (HIV-infected MDR-TB without XDR)
New cases 1990–1994 1,183** 1994–1998 464** 1998–2002 185** 2002–2006 −104** 2006–2009 −517** 2009–2017 −218**
Incidence rate 1990–1993 0.062** 1993–1996 0.027** 1996–2000 0.010** 2000–2005 −0.002** 2005–2009 −0.021** 2009–2017 −0.010**
Prevalent cases 1990–1994 1,268** 1994–1999 786** 1999–2002 282** 2002–2006 −3 2006–2013 −190** 2013–2017 −356**
Prevalence rate 1990–1993 0.065** 1993–1996 0.038** 1996–2000 0.025** 2000–2005 −0.0003 2005–2013 −0.011** 2013–2017 −0.017**
Deaths 1990–1996 215** 1996–2003 117** 2003–2008 −15 2008–2012 −61** 2012–2015 −178** 2015–2017 −73
Mortality rate 1990–1996 0.011** 1996–2003 0.004** 2003–2008 −0.002** 2008–2012 −0.003** 2012 –2015 −0.007** 2015–2017 −0.003*
HIV-infected extensively drug-resistant tuberculosis (HIV-infected XDR-TB)
New cases 1990–1993 10** 1993–1996 17** 1996–1999 35** 1999–2005 30** 2005–2017 3** – –
Incidence rate 1990–1995 0.001** 1995–2002 0.001** 2002–2005 0.001** 2005–2017 −0.001 to 0 – – – –
Prevalent cases 1990–1993 9** 1993–1996 23** 1996–2004 44** 2004–2009 32** 2009–2014 16** 2014–2017 8**
Prevalence rate 1990–1995 0.001** 1995–2004 0.002** 2004–2009 0.001** 2009–2014 <0.001** 2014–2017 <0.001 – –
Deaths 1990–1993 1 1993–1998 16** 1998–2005 26** 2005–2012 13** 2012–2015 −23** 2015–2017 −4
Mortality rate 1990–1994 <0.001 1994–2004 0.001** 2004–2008 0.001** 2008–2012 <0.001 2012–2015 −0.001** 2015–2017 −0.001 to 0
Incidence, prevalence and mortality rates are age-standardized, per 100,000 population. The slope in each time period represents a unit of change per year. The slope is significantly different 
from zero (*, P<0.05; **, P<0.01). DS-TB, drug-susceptible tuberculosis; MDR-TB without XDR, multidrug-resistant tuberculosis without extensive drug resistance; XDR-TB, extensive drug-
resistant tuberculosis.
Table S2 Trend analysis on the number and rate for incidence, prevalence and mortality (1990–2017) of HIV-infected drug-susceptible tuberculosis (HIV-infected DS-TB) in the top three countries of 
East Asia and the Pacific based on 2017
Measures
Trend 1 Trend 2 Trend 3 Trend 4 Trend 5 Trend 6
Years Slope Years Slope Years Slope Years Slope Years Slope Years Slope
New cases
Indonesia 1990–1994 14,197** 1994–1997 6,956** 1997–2005 5,849** 2005–2009 4,355** 2009–2017 3,224** – –
China 1990–1994 1,845** 1994–2005 545** 2005–2010 −1,518** 2010–2014 284* 2014–2017 824** – –
Myanmar 1990–1994 2,401** 1994–1999 1,713** 1999–2004 1,328** 2004–2007 151 2007–2013 −941** 2013–2017 −1,972**
Incidence rate
Indonesia 1990–1993 7.822** 1993–1996 3.796** 1996–2007 1.622** 2007–2017 0.857** – – – –
Laos 1990–1996 1.161** 1996–1999 1.874** 1999–2002 2.755** 2002–2005 0.844** 2005–2012 −0.258** 2012–2017 −1.172**
Myanmar 1990–1994 5.770** 1994–1999 3.355** 1999–2004 2.156** 2004–2007 −0.382** 2007–2013 −2.283** 2013–2017 −3.991**
Prevalent cases
Indonesia 1990–1994 16,223** 1994–1997 10,013** 1997–2010 8,947** 2010–2007 5,130** – – – –
China 1990–1995 1,798** 1995–2000 2,069** 2000–2005 700** 2005–2013 1,838** 2013–2017 2,332** – –
Vietnam 1990–1998 902** 1998–2005 1,221** 2005–2011 −52 2011–2017 369** – – – –
Prevalence rate
Indonesia 1990–1993 8.801** 1993–1996 5.054** 1996–2010 2.776** 2010–2017 1.363** – – – –
Laos 1990–1996 1.469** 1996–2000 2.485** 2000–2005 3.787** 2005–2009 1.819** 2009–2013 −0.043** 2013–2017 −1.318**
Myanmar 1990–1993 7.543** 1993–1998 5.201** 1998–2004 3.711** 2004–2007 0.047 2007–2012 −2.169** 2012–2017 −5.989**
Deaths
Indonesia 1990–1995 42** 1995–2001 73** 2001–2010 124** 2010–2013 276** 2013–2017 98** – –
Vietnam 1990–1996 144** 1996–2003 257** 2003–2006 78* 2006–2009 −139** 2009–2014 4 2014–2017 −67**
China 1990–1993 177** 1993–2003 85** 2003–2012 −96** 2012–2017 99** – – – –
Mortality rate
Myanmar 1990–1992 0.213 1992–1997 0.757** 1997–2005 1.085** 2005–2009 −0.279** 2009–2014 −1.203** 2014–2017 −0.925**
Vietnam 1990–1997 0.218** 1997–2002 0.281** 2002–2005 0.104** 2005–2009 −0.192** 2009–2014 −0.048** 2014–2017 −0.095**
Thailand 1990–1993 1.216** 1993–1996 0.660** 1996–1999 −0.049 1999–2007 −0.462** 2007–2011 −0.138** 2011–2017 −0.009
*, P<0.05; **, P<0.01. 
